Roche unearths flu treatment

Roche’s Genentech unit has licensed an experimental new technology that uses antibodies to fight influenza, including H1N1 swine flu, Harvard’s Dana Farber Cancer Institute said yesterday. Dana Farber said it and the Sanford-Burnham Medical Research Institute had signed a licence agreement with Genentech, giving the company exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group one influenza viruses.